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Abstract
Numerous preclinical studies have shown that the
naturally-occurring polyphenol resveratrol may
produce health-beneficial effects in a variety of
disorders, including cancer, diabetes, Alzheimer, and
cardiovascular diseases. Resveratrol has entered
clinical trials for the prevention and treatment of
several of these disorders. This polyphenol is also
available in the market as a dietary supplement.
Experimental data have shown, however, that
resveratrol induces DNA damage in a variety of cells.
Here we review such evidence and evaluate the
cytotoxicity of resveratrol (MTT assay) in cells deficient
in several major DNA repair pathways (i.e.,
homologous recombination, non-homologous end
joining, base excision repair, nucleotide excision repair,
mismatch repair, and Fanconi anemia repair). Cells
deficient in base excision repair (EM9), nucleotide
excision repair (UV4 and UV5) and Fanconi Anemia
(KO40)  were  s l igh t l y  hypersens i t i ve  to
resveratrol-induced cytotoxicity with respect to their
parental cells (AA8). Our results suggest that these
pathways may participate in the repair of the DNA
damage induced by resveratrol and that deficiencies in
these pathways may confer hypersensitivity to the
genotoxic activity of this dietary constituent.    
Introduction
Numerous studies have been conducted to assess the
possible health benefits of resveratrol. Preclinical
studies suggest that this dietary occurring stilbene
may confer protect ion against metabol ic,
cardiovascular and other age-related complications,
including neurodegeneration and cancer (1-19). Many
clinical trials have been conducted, or are ongoing or
recruiting participants, to evaluate the health benefits
of resveratrol in humans (https://clinicaltrials.gov/).
These trials have not shown relevant health benefits
so far. Because resveratrol is a natural constituent of
grapes and because grape consumption is not
associated with any type of toxicity, it is believed that
the potential health benefits of this compound will be
achieved without toxicity. This may explain why
resveratrol is readily available in the market and is
widely consumed as a dietary constituent.
Large cancer chemoprevention clinical trials have
demonstrated, however, that some dietary
constituents (i.e. beta-carotene, vitamin E) significantly
increased cancer risk (lung and prostate cancer,
respectively) when used in the form of dietary
supplements (20;21). The toxicity of some dietary
constituents may be mediated by their prooxidant and
DNA damaging activities (22-25). Inhibition of DNA
topoisomerase activity may also lead to genotoxic
damage, and several dietary constituents induce
topoisomerase-mediated DNA damage (23-43).
Although resveratrol is generally regarded as a safe
antioxidant, evidence suggests that resveratrol may
also induce genotoxicity, which may be mediated by
its pro-oxidant and topoisomerase poisoning activities
(27;30;37;38;44;45). Table 1 shows several reports in
which the DNA-damaging activity of resveratrol has
been evaluated in cells.
The DNA damage effect of resveratrol could be
enhanced in cells with specific DNA repair deficiencies.
For example, BRCA2 is a DNA repair gene involved in
the repair of double-strand DNA breaks. People with
mutations in BRCA2 have an increased cancer risk
because they are unable to properly repair this type of
DNA damage. These individuals would be
hypersensitive to the DNA damaging activity of dietary
agents that induce double-strand DNA breaks. People
without inherited mutations in DNA repair genes may
develop sporadic mutations in these genes during a
possible carcinogenesis process, and may therefore
become hypersensitive to dietary agents inducing
specific types of DNA damage. It is important,
therefore, to evaluate the cytotoxicity of common
dietary constituents in cells lacking an intact DNA
damage repair capacity.
Several major DNA repair pathways are known to
participate in the repair of most types of DNA damage.
These pathways include homologous recombination
(HR) repair, non-homologous end joining (NHEJ)
repair, base excision repair (BER), nucleotide excision
repair (NER), mismatch repair (MMR), Fanconi
anaemia (FA) repair. The choice of each of these
pathways mainly depends on the type of DNA damage
that occurs, although other factors (such as the phase
of the cell cycle) are known to play a role. Most of
these pathways incorporate a similar set of
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coordinated processes that include the detection of
DNA damage, the accumulation of DNA repair factors
at the site of damage and, finally, the physical repair of
the lesion (46;47). HR is involved in the repair of DNA
double-strand breaks, DNA inter-strand cross links
and damage encountered during DNA replication.
NHEJ is also involved in the repair of DSBs. In
contrast to HR, NHEJ ligates the two ends of a DSB
without the requirement of a homologous template.
NHEJ is error prone, because this process can cause
the deletion or mutation of nucleotides around the
DSB site. NHEJ occurs throughout the cell cycle, but
mainly in the G0/G1 phases. The BER pathway
repairs damaged bases (a single base or a short
strand containing a damaged base), abasic sites and
single strand breaks. Whereas BER repairs small base
damages, NER repairs some of the bulkier DNA
lesions that distort the DNA helical structure, such as
those induced by UV radiation and by some chemical
carcinogens. NER is divided into two sub-pathways:
the global genome NER (GG-NER) and the
transcription coupled NER (TC-NER). GG-NER
identifies and removes damages all over the genome
whereas TC-NER repairs actively transcribed genes.
Mismatch repair (MMR) plays an important role in
maintaining genomic stability by repairing small
insertions, deletions and base-base mismatches
caused by spontaneous and induced base
deamination, oxidation, methylation and replication
errors. Fanconi Anemia (FA) is a disorder
characterized by chromosomal instability, cancer
susceptibility, and a profound sensitivity to agents that
produce DNA interstrand cross-links. The FA pathway
is thought to mediate the repair of DNA interstrand
cross-links at replication forks, possibly by facilitating
ATR- and ATM-dependent checkpoint signaling and
activating HR repair (46;47). In this work, we have
used cell lines with defects HR, NHEJ, BER, NER,
MMR and FA to assess the effect of specific DNA
repair deficiencies on the cytotoxicity of resveratrol.
Methods
Chemicals and Cell lines
Resveratrol was purchased from Sigma. The effect of
resveratrol was studied in cells deficient in the
following DNA repair pathways: Homologous
recombination (HR), Non-homologous recombination
(NHEJ), Base excision repair (BER), Nucleotide
excision repair (NER), Mismatch repair (MMR) and
Fanconi anemia repair (FA) (47). Table 2 shows
additional information on these DNA repair deficient
cell lines and on their parental non-deficient
counterparts. The cell lines were maintained in DMEM
supplemented with 2 mM glutamine, 50 µg/mL
penicillin, 50 µg/mL streptomycin and 10% fetal bovine
serum, and were cultured at 37°C in a humidified
atmosphere containing 5% CO2 (48;49).
MTT cell proliferation assay
The MTT assay is a colorimetric technique that allow
the quantitative determination of cell viability (50). It is
based on the capability of viable cells to transform the
MTT salt  (3-(4,5-dimethylthiazol-2-yl)-2,5
diphenyltetrazolium bromide) into formazan dye.
Exponentially growing cells were seeded into 96-well
plates and resveratrol was added 24 h later. After a
drug exposure period of 48h, cells were incubated with
MTT for 5h.  Then, 80 µl 20% SDS in 0.02 M HCl were
added, and the plates were incubated for 10 h at 37°C
before measuring optical densities at 540 nm on a
multiwell plate spectrophotometer reader. Cell viability
was expressed as percentage in relation to controls.
For statistical analysis we used the t-test (paired,
two-tailed). All data were averaged from at least two
independent experiments and were expressed as the
means ± standard error of the means (SEM).
Results and Discussion
Evidence has accumulated that some dietary
constituents may induce toxicity when used at higher
concentrations than those achieved in a normal diet.
For example, s ince the ant ioxidant agent
beta-carotene is found in vegetables and fruits and
because eating vegetables and fruits is associated
with a reduced risk of cancer, it seemed reasonable to
think that taking high doses of beta-carotene
supplements might reduce cancer risk. Preclinical
studies supported the possible cancer preventive
activity of this dietary constituent. In three major
clinical trials, people were given high doses of
beta-carotene (20-30 mg, which are approximately
10-times higher than those found in a diet rich in fruits
and vegetables) in an attempt to prevent lung cancer
and other cancers. These trials were stopped ahead of
schedule because two of them found beta-carotene
supplements to be associated with a higher risk of
lung cancer (20). It has also been found in another
major  chemoprevent ion t r ia l  that  d ietary
supplementation with vitamin E significantly increased
the risk of prostate cancer among healthy men(21).
The pro-oxidant activity of beta-carotene and vitamin E
may account for their toxicity, because pro-oxidant
compounds can increase the cellular levels of reactive
oxygen species (ROS), which are known to induce
carcinogenic effects. The inhibition of DNA
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topoisomerase is also known to lead to carcinogenic
effects, and some dietary constituents are able to
induce topoisomerase-mediated DNA damage
(25;51;52).
Because resveratrol can both induce pro-oxidant
activity and inhibit DNA topoisomerase function
(27;30;37;38;44;45), and because these activities can
lead to DNA damage, it is not surprising that this
dietary agent can induce DNA damage in a variety of
cells (Table 1). Some reports show that resveratrol
induces DNA damage in the low micromolar range
(Table 1). Human studies have shown that
supplementation of resveratrol leads to plasma
concentrations in the nanomolar-micromolar range
(53-55). This suggests that some tissues may be
exposed to carcinogenic concentrations of resveratrol
after dietary supplementation. This effect may be more
pronounced in people with heritable defects in genes
involved in DNA damage repair. During a possible
carcinogenic event, premalignant cells may acquire
mutations in DNA repair genes. This would make them
hypersensitive to the carcinogenic activity of
compounds that induce types of DNA damage that
require these DNA repair genes for repair. Therefore,
we considered relevant to evaluate the effect of
specific DNA repair deficiencies on the cytotoxicity of
resveratrol.
Our results show that cells lacking particular DNA
repair genes are sl ight ly but signif icant ly
hypersensitive to the cytotoxicity of resveratrol (Figure
1). In some cases, differences between the deficient
cell line and the parental cell line were observed in the
low micromolar range. These differences were mild
and require further investigation. However, our
preliminary findings support the view that the
supplementation of resveratrol at high concentrations
may induce carcinogenic effects under specific
conditions.
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